Table 2 Grade 3 and 4 adverse events occurring in more that 2% of patients on this phase II study of erlotinib
From: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
Grade 3/4 toxicities | n (%) patients | n (%) cycles |
|---|---|---|
Gr. 4 Constipation | 2 (5) | 2 (2) |
Gr. 4 Abdominal pain/cramping | 1 (3) | 1 (1) |
Gr. 4 Bone pain (left hip/right ankle) | 1 (3) | 1 (1) |
Gr. 3 Diarrhoea | 4 (11) | 4 (4) |
Gr. 3 Rash/desquamation | 4 (11) | 4 (4) |
Gr. 3 Vomiting | 3 (8) | 3 (3) |
Gr. 3 Pain | 2 (5) | 3 (3) |
Gr. 3 Haematuria | 2 (5) | 4 (4) |
Gr. 3 Hyperglycaemia | 2 (5) | 3 (3) |
Gr. 3 Alkaline phosphatase | 2 (5) | 2 (2) |
Gr. 3 Nausea | 2 (5) | 2 (2) |
Gr. 3 Prothrombin time | 2 (5) | 2 (2) |
